Advertisement

Topics

Novartis Drug Delivers Superior Reductions In Retinal Thickness During Trial

06:37 EST 13 Nov 2017 | Pharmaceutical Processing

Brolucizumab, the first and only vascular endothelial growth factor to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-inferiority vs aflibercept.
Contributed Author: 
Novartis Pharmaceuticals Corp.

Original Article: Novartis Drug Delivers Superior Reductions In Retinal Thickness During Trial

NEXT ARTICLE

More From BioPortfolio on "Novartis Drug Delivers Superior Reductions In Retinal Thickness During Trial"

Advertisement
Quick Search
Advertisement
Advertisement